Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection

Wednesday, May 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a clinical study examining the safety and antiviral effects of ALG-000184 in combination with Entecavir for treating untreated HBeAg-positive subjects with chronic Hepatitis B virus infection. The treatment is administered orally at a daily dose of 300 mg over a period of up to 96 weeks. This research aims to provide insights into effective management strategies for chronic HBV infection.
Price reaction · baseline $4.36 (2025-05-07 close) · hit after-hours · 5 other ALGS headline(s) in the window, move may be shared
day 0 close
+11.7%
day 1
+2.8%
day 3 · peak
+36.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study focuses on a novel treatment for chronic Hepatitis B.
  • Combination therapy may enhance antiviral effects.
  • Long duration of treatment (up to 96 weeks) could provide comprehensive data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a novel antiviral treatment being studied for chronic Hepatitis B.

How long is the treatment duration for the study?

The treatment duration in the study is up to 96 weeks.

What is the target population for this study?

The study targets untreated HBeAg-positive subjects with chronic Hepatitis B.

What is the dosage of ALG-000184 in the trial?

The trial administers ALG-000184 at a daily dose of 300 mg.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 chronic Hepatitis B Entecavir clinical trial HBeAg-positive
Last updated: May 7, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →